Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
The path from university research to start-up company is an essential part of the innovation economy. This Outlook presents some star spin-offs that took root after seeds of scientific insight fell on fertile commercial soil.
Our annual survey highlights startups tackling intractable viruses with new vaccine design, engineering a reliable source of platelets, universalizing cell therapies, improving cancer screening, developing RNA-editing platforms and targeting protein–RNA interactions. Michael Eisenstein, Ken Garber, Caroline Seydel and Laura DeFrancesco report.
A detailed look at the economic impact of university-licensed life science startups across the United States reveals vast differences in the effectiveness of different regions to create ventures and sustain them as viable entities.
An analysis of Massachusetts Institute of Technology intellectual property licenses in the life sciences not only provides a window on commercialization success but also a case study for transparency in understanding technology transfer performance.